Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of AZD2373, an antisense oligonucleotide targeting APOL1

被引：0

作者：

Greasley, Peter J. ^{[1
]}

Agrawal, Nikhil ^{[2
]}

Althage, Magnus ^{[3
]}

Sanchez, Jose ^{[4
]}

Kirk, Sarah ^{[5
]}

Egeland, Erlend Johannessen ^{[6
]}

Astrand, Magnus ^{[6
]}

Westergren, Helena ^{[7
]}

Sherwood, James ^{[8
]}

Mccarthy, Michael ^{[9
]}

Patel, Uptal ^{[2
]}

Macphee, Iain ^{[10
]}

机构：

[1] BioPharmaceut R&D, Early Clin Dev, Cardiovasc Renal & Metab, Res & Early Dev, Gothenburg, Sweden

[2] BioPharmaceut R&D, Res & Early Dev, Cardiovasc Renal & Metab, Early Clin Dev, Gaithersburg, MD USA

[3] BioPharmaceut R&D, Translat Sci & Expt Med, Early Cardiovasc Renal & Metab, Gothenburg, Sweden

[4] AstraZeneca, Early Biometr Stat Innovat, Data Sci & Artificial Intelligence R&D, Gothenburg, Sweden

[5] AstraZeneca, Data Sci & Artificial Intelligence R&D, Early Biometr Stat Innovat, Cambridge, England

[6] AstraZeneca, Clin Pharmacol & Quantitat Pharmacol, Clin Pharmacol & Safety Sci R&D, Gothenburg, Sweden

[7] AstraZeneca, Precis Med & Biosamples Biopharmaceut, Precis Med & Biosamples Oncol R&D, Gothenburg, Sweden

[8] AstraZeneca, Precis Med & Biosamples Biopharmaceut, Precis Med & Biosamples Oncol R&D, Cambridge, England

[9] AstraZeneca, BioPharmaceut R&D, Cardiovasc Renal & Metab, Projects Res & Early Dev,Res & Early Dev, Gaithersburg, MD USA

[10] AstraZeneca, BioPharmaceut R&D, Early Clin Dev, Res & Early Dev,Cardiovasc Renal & Metab, Cambridge, England

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

1003

引用

页码：I1134 / I1135

页数：2

共 50 条

[21] Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp
Ericsson, Hans
Roshammar, Daniel
Wollbratt, Maria
Heijer, Maria
Persson, Maria
Ueda, Shinya
Leonsson-Zachrisson, Maria
Norjavaara, Ensio
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (11) : 765 - 777
[22] Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses
Moore, KHP
Hussey, EK
Shaw, S
Fuseau, E
Duquesnoy, C
Pakes, GE
CEPHALALGIA, 1997, 17 (04) : 541 - 550
[23] Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults
Bertz, R.
Donohue, M. K.
Madonia, J.
Bhardwaj, R.
Stringfellow, J.
Anderson, M.
Stock, D. A.
Morris, B. A.
Coric, V
Croop, R.
HEADACHE, 2022, 62 : 122 - 122
[24] Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects
Jinjie He
Guoying Cao
Jicheng Yu
Jingjing Wang
Nengneng Cheng
Jufang Wu
Jing Zhang
Xiaojie Wu
Basheng Zhang
Jiayan Lu
Shangzhi Chen
Clinical Drug Investigation, 2021, 41 : 89 - 97
[25] Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects
He, Jinjie
Cao, Guoying
Yu, Jicheng
Wang, Jingjing
Cheng, Nengneng
Wu, Jufang
Zhang, Jing
Wu, Xiaojie
Zhang, Basheng
Lu, Jiayan
Chen, Shangzhi
CLINICAL DRUG INVESTIGATION, 2021, 41 (01) : 89 - 97
[26] Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-Ascending Doses of Sunobinop in Healthy Participants
Cipriano, Alessandra
Kapil, Ram P.
Zhou, Mingyan
Shet, Manjunath S.
Whiteside, Garth T.
Willsie, Sandra K.
Harris, Stephen C.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (07): : 790 - 800
[27] Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ascending multiple doses of SRA-333 in healthy subjects
Raje, SV
Plotka, A
Parks, V
Patat, A
Chassard, D
NEUROBIOLOGY OF AGING, 2004, 25 : S215 - S215
[28] Safety, tolerability, pharmacokinetics and pharmacodynamics of a liver-targeting ACC inhibitor (PF-05221304) following single and multiple oral doses
Bergman, A.
Gonzalez, S. C.
Tarabar, S.
Saxena, A.
Esler, W.
Amin, N.
JOURNAL OF HEPATOLOGY, 2018, 68 : S582 - S582
[29] The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses
Yang, Yuanxun
Yu, Lei
Sheng, Zejuan
Lin, Hui
Weng, Zuyi
Song, Wei
Cao, Bei
Zhao, Yu
Gao, Yingsheng
Ni, Shumao
Wang, Huimin
Ma, Tingting
Huang, Lei
Sun, Caixia
Li, Juan
FRONTIERS IN PHARMACOLOGY, 2024, 15
[30] ASCENDING MULTIPLE-DOSE STUDY WITH PONESIMOD, A SELECTIVE SIP1 RECEPTOR AGONIST: TOLERABILITY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS
Brossard, P.
Maatouk, H.
Halabi, A.
Dingemanse, J.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S93 - S93

← 1 2 3 4 5 →